A first-of-its-kind flu shot is one step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for approval. The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older. Moderna is...
FDA panel recommends mRNA flu vaccine for older adults
Political Leaning Analysis
Score: 0.00 •
Center / Neutral
Left
Center
Right
Story Timeline
Wed 23:00 - The Hill
FDA vaccine panel set to review Moderna mRNA flu shot
Thu 22:31 - The Hill
FDA panel recommends mRNA flu vaccine for older adults
Thu 23:37 - The Hill
FDA panel gives nod to Moderna flu shot